Short answer
Inhibikase Therapeutics, Inc. (IKT) filed an 8-K current report with the SEC on August 26, 2026 reporting Item 4.01 (Changes in Registrant's Certifying Accountant). CohnReznick dismissed effective August 21, 2026; Deloitte appointed immediately for fiscal 2026.
- This filing includes Item 4.01, an item that often signal trouble.
Inhibikase Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 4.01 · Changes in Registrant's Certifying Accountant
- CohnReznick dismissed effective August 21, 2026; Deloitte appointed immediately for fiscal 2026
- Prior audit opinions for 2025 and 2024 contained no adverse opinion, disclaimer, or qualification
- No accounting or auditing disagreements reported with CohnReznick through dismissal
- Previously disclosed material weakness in internal controls was remediated in September 2024
- Auditor transition appears administrative, with no reported Deloitte consultations involving disagreements or reportable events
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Inhibikase Therapeutics, Inc. 8-K filings
Get the next IKT 8-K as it lands
Follow IKT for push alerts, or ask the research agent what this filing means.